Mao Jianbo, Zhang Caiyun, Liu Chenyi, Shen Lijun, Lao Jimeng, Shao Yirun, Chen Yiqi, Tao Jiwei
Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chicago College of Optometry, Midwestern University, Downers Grove, IL, USA.
J Ophthalmol. 2019 May 7;2019:7409426. doi: 10.1155/2019/7409426. eCollection 2019.
To evaluate the efficacy and safety of conbercept for patients with chronic central serous chorioretinopathy (CSC).
A retrospective clinical study. Thirty-one patients (35 eyes) with chronic CSC were given intravitreal injections of conbercept and followed up for at least 6 months. Observed indicators included best-corrected visual acuity (BCVA), central macular thickness (CMT), and resolution of subretinal fluid (SRF). Serial changes in BCVA and CMT were analyzed by using repeated measures analysis of variance.
During the 6-month follow-up, the mean number of injections required and performed was 1.77 ± 0.60. The logMAR BCVA was 0.48 ± 0.26 at the baseline, 0.34 ± 0.26, 0.30 ± 0.26, 0.27 ± 0.26, 0.24 ± 0.26, and 0.23 ± 0.26 at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively ( = 27.173, < 0.05). CMT was 313.74 ± 144.51 m at the baseline and decreased to 263.49 ± 120.44 m, 225.91 ± 91.98 m, 195.77 ± 66.69 m, 189.74 ± 65.41 m, and 199.49 ± 81.50 m at 2-week and 1-, 2-, 3-, and 6-month follow-ups, respectively ( = 18.093, < 0.05). Full resolution of SRF was achieved in 8 (22.9%) eyes at 1 month, 16 (45.7%) eyes at 2 months, 22 (62.9%) eyes at 3 months, and 27 (77.1%) eyes at 6 months after the initial treatment of anti-VEGF injection. No severe adverse event was noted relevant to the therapy.
Intravitreal injection of conbercept may effectively reduce the CMT and improve the BCVA in chronic CSC in a short term of 6 months.
评估康柏西普治疗慢性中心性浆液性脉络膜视网膜病变（CSC）患者的疗效和安全性。
一项回顾性临床研究。对31例（35只眼）慢性CSC患者进行玻璃体内注射康柏西普，并随访至少6个月。观察指标包括最佳矫正视力（BCVA）、中心黄斑厚度（CMT）和视网膜下液（SRF）的消退情况。采用重复测量方差分析对BCVA和CMT的系列变化进行分析。
在6个月的随访期间，所需及实际进行的平均注射次数为1.77±0.60次。基线时logMAR BCVA为0.48±0.26，在2周及1、2、3和6个月随访时分别为0.34±0.26、0.30±0.26、0.27±0.26、0.24±0.26和0.23±0.26（F = 27.173，P < 0.05）。基线时CMT为313.74±144.51μm，在2周及1、2、3和6个月随访时分别降至263.49±120.44μm、225.91±91.98μm、195.77±66.69μm、189.74±65.41μm和199.49±81.50μm（F = 18.093，P < 0.05）。在抗VEGF注射初始治疗后1个月、2个月、3个月和6个月时，分别有8只眼（22.9%）、16只眼（45.7%）、22只眼（62.9%）和27只眼（77.1%）的SRF完全消退。未观察到与治疗相关的严重不良事件。
玻璃体内注射康柏西普在6个月的短期内可有效降低慢性CSC患者的CMT并改善BCVA。
